Future Applications in ES-SCLC: Targeting DLL3 and Emerging Evidence for T-cell Engagers

Gain in-depth knowledge on the mechanism of action for T-cell–engaging therapies targeting DLL3 in extensive-stage small-cell lung cancer (ES-SCLC) and expert insights on how these agents will impact your clinical practice in this text module with accompanying slides.

Share

Program Content

Activities

Targeting DLL3 in ES-SCLC
Future Applications in ES-SCLC: Targeting DLL3 and Emerging Evidence for T-Cell Engagers
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: November 07, 2024

Expires: May 06, 2025

Activities

Targeting DLL3 in ES SCLC
Future Applications in ES-SCLC: Targeting DLL3 and Emerging Evidence for T-Cell Engagers
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 07, 2024

Expires: May 06, 2025

Faculty

cover img faculity

Carl M. Gay, MD, PhD

Assistant Professor
Thoracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.